Table II.
Comparison of upregulated and downregulated genes between polypoid and ulcerative colorectal cancer.
| Access no. | Gene name | Incidence | Polypoid fold changea (mean + SD) | Incidence | Ulcerative fold changea (mean + SD) | P-value |
|---|---|---|---|---|---|---|
| Upregulated genes | ||||||
| Hs.2962 | S100 calcium binding protein P | 8 | 8.203±5.326 | 5 | 3.106±2.885 | 0.032 |
| Hs.789 | Chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, α) | 7 | 5.212±4.858 | 4 | 2.309±1.620 | 0.131 |
| Hs.423 | Pancreatitis-associated protein | 6 | 6.149±8.842 | 5 | 6.042±6.340 | 0.978 |
| Hs.118787 | Transforming growth factor, β-induced, 68 kDa | 6 | 4.416±3.564 | 4 | 2.437±1.924 | 0.189 |
| Hs.89690 | GRO3 oncogene | 6 | 5.094±4.650 | 3 | 1.492±2.077 | 0.065 |
| Hs.458414 | Hypothetical protein MGC27165 | 5 | 2.628±1.244 | 7 | 3.290±1.204 | 0.298 |
| Hs.4158 | Regenerating islet-derived lβ (pancreatic stone protein, pancreatic thread protein) | 5 | 7.385±7.794 | 6 | 6.764±7.999 | 0.877 |
| Hs.155596 | BCL2/adenovirus E1B 19 kDa interacting protein 2 | 5 | 4.435±6.159 | 6 | 3.742±5.209 | 0.812 |
| Hs.273321 | Differentially expressed in hematopoietic lineages | 5 | 5.795±6.185 | 6 | 4.964±6.661 | 0.8 |
| Hs.129778 | Serine protease inhibitor, Kazal type 4 | 5 | 4.194±5.219 | 4 | 4.770±6.989 | 0.93 |
| Hs.105484 | Regenerating gene type IV | 4 | 2.061±2.532 | 4 | 1.820±1.765 | 0.629 |
| Downregulated genes | ||||||
| Hs.76325 | Immunoglobulin J polypeptide, linker protein for immunoglobulin α and mu polypeptides | 7 | 5.855 | 6 | 3.904 | 0.679 |
| Hs.1650 | Downregulated in adenoma | 8 | −10.268±6.787 | 8 | −5.757±2.575 | 0.101 |
| Hs.57975 | Calsequestrin 2 (cardiac muscle) | 5 | −2.304±1.150 | 4 | −1.835±1.478 | 0.491 |
| Hs.381097 | Metallothionein 1F (functional) | 5 | −2.864±2.134 | 6 | −3.798±2.099 | 0.392 |
| Hs.46847 | TRAF and TNF receptor-associated protein | 6 | −2.914±1.039 | 4 | −2.636±1.379 | 0.655 |
| Hs.78224 | Ribonuclease, RNase A family, 1 (pancreatic) | 5 | −2.626±2.151 | 4 | −2.684±2.172 | 0.958 |
| Hs.153261 | Immunoglobulin heavy constant mu | 5 | −4.518±5.378 | 5 | −6.765±10.794 | 0.606 |
| Hs.248112 | γ-aminobutyric acid (GABA) A receptor, α 4 | 5 | −3.895±5.458 | 4 | −3.681±6.296 | 0.943 |
| Hs.366 | Hypothetical protein MGC27165 | 7 | −6.089±7.404 | 6 | −5.718±3.426 | 0.751 |
| Hs.433205 | Metallothionein 1E (functional) | 5 | −3.004±2.137 | 6 | −4.349±2.372 | 0.253 |
| Hs.326248 | Programmed cell death 4 (neoplastic transformation inhibitor) | 7 | −3.289±1.534 | 5 | −2.593±2.049 | 0.455 |
| Hs.84905 | Cytokeratin 20 | 7 | −4.440±3.257 | 4 | −3.041±2.773 | 0.393 |
| Hs.155048 | Lutheran blood group (Auberger b antigen included) | 3 | −3.797±6.734 | 7 | −4.312±2.989 | 0.548 |
| Hs.87497 | Butyrophilin, subfamily 3, member A2 | 5 | −3.516±2.365 | 4 | −2.770±2.654 | 0.562 |
a
Fold change, corresponding to the ‘signal ratio’ of tumor/normal, was calculated from the ‘signal log ratio’.